$34.27 Million in Sales Expected for Insys Therapeutics, Inc. (INSY) This Quarter

Brokerages predict that Insys Therapeutics, Inc. (NASDAQ:INSY) will report sales of $34.27 million for the current quarter, Zacks reports. Three analysts have made estimates for Insys Therapeutics’ earnings. The highest sales estimate is $38.00 million and the lowest is $30.82 million. Insys Therapeutics reported sales of $54.86 million during the same quarter last year, which would suggest a negative year over year growth rate of 37.5%. The company is scheduled to announce its next earnings results on Monday, April 2nd.

On average, analysts expect that Insys Therapeutics will report full-year sales of $34.27 million for the current fiscal year, with estimates ranging from $140.03 million to $155.00 million. For the next financial year, analysts forecast that the firm will report sales of $169.19 million per share, with estimates ranging from $156.45 million to $186.13 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Insys Therapeutics.

Several equities analysts have recently issued reports on INSY shares. BidaskClub downgraded shares of Insys Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Piper Jaffray Companies set a $10.00 price objective on shares of Insys Therapeutics and gave the company a “hold” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Insys Therapeutics in a report on Thursday, August 3rd. Royal Bank Of Canada cut their price objective on shares of Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, August 4th. Finally, Zacks Investment Research downgraded shares of Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Insys Therapeutics has a consensus rating of “Hold” and an average target price of $9.38.

Insys Therapeutics (NASDAQ:INSY) traded down $0.05 on Friday, hitting $5.16. 485,500 shares of the stock traded hands, compared to its average volume of 907,903. Insys Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.02.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/12/34-27-million-in-sales-expected-for-insys-therapeutics-inc-insy-this-quarter.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp grew its stake in shares of Insys Therapeutics by 3.4% during the 2nd quarter. State Street Corp now owns 471,514 shares of the specialty pharmaceutical company’s stock worth $5,966,000 after purchasing an additional 15,570 shares during the period. Northern Trust Corp grew its stake in shares of Insys Therapeutics by 3.2% during the 2nd quarter. Northern Trust Corp now owns 314,825 shares of the specialty pharmaceutical company’s stock worth $3,983,000 after purchasing an additional 9,906 shares during the period. Geode Capital Management LLC grew its stake in shares of Insys Therapeutics by 9.7% during the 1st quarter. Geode Capital Management LLC now owns 305,044 shares of the specialty pharmaceutical company’s stock worth $3,206,000 after purchasing an additional 26,913 shares during the period. FMR LLC grew its stake in shares of Insys Therapeutics by 4.7% during the 2nd quarter. FMR LLC now owns 254,588 shares of the specialty pharmaceutical company’s stock worth $3,221,000 after purchasing an additional 11,504 shares during the period. Finally, Strs Ohio lifted its position in shares of Insys Therapeutics by 40.0% during the 2nd quarter. Strs Ohio now owns 175,000 shares of the specialty pharmaceutical company’s stock valued at $2,213,000 after buying an additional 50,000 shares in the last quarter. 25.42% of the stock is currently owned by institutional investors and hedge funds.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply